GRTS - グリットスト―ン・オンコロジ― （Gritstone Oncology Inc.） グリットスト―ン・オンコロジ―GRTSのチャート
GRTSの企業情報
| symbol | GRTS |
|---|---|
| 会社名 | Gritstone Oncology Inc （グリットスト―ン・オンコロジ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Gritstone Oncology Inc. is an immuno-oncology company that develops tumor-specific cancer immunotherapies to fight multiple cancer types. The Company focuses to identify and deploy therapeutic neo-antigens from individual patients' tumors to develop treatments for lung cancer. It provides Gritstone EDGE which is a tumor-specific neo-antigen (TSNA) prediction platform that predicts the presence of a patient’s TSNA on tumor cells. It also develops and manufactures a patient-specific therapeutic to direct a robust thymus (T) cell response to those TSNA predicted to be presented on the patient’s tumor. In its GRANITE-001 product candidate each of the viral prime and RNA boost immunizations contain a patient-specific set of predicted TSNA and the viral prime and RNA boost in its SLATE product candidate series contains a fixed TSNA cassette that is designed for the subset of patients with tumor neoantigens. グリットスト―ン・オンコロジ―は米国の新薬開発企業。AI技術を利用したがん治療のパイプラインを開発。各患者の腫瘍の個々の性質に焦点を当て、同社のAIプラットフォ―ムGritstone EDGEの予測能力を組み合わせることにより、複数のタイプのがんと闘う患者向けに個人化免疫療法を開発、提供する。本社所在地はカリフォルニア州エメリ―ビル。 Gritstone Oncology, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars-first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient's immune system to specifically attack and destroy disease-causing cells. The company's lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an 'off-the-shelf' shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. The company also has a bispecific antibody (BiSAb) program for solid tumors in lead optimization. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, as well as a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. |
| 本社所在地 | 5858 Horton Street Suite 210 Emeryville CA 94608 USA |
| 代表者氏名 | Andrew R. Allen アンドリュー・R・アレン |
| 代表者役職名 | President Chief Executive Officer Co-Founder Director |
| 電話番号 | +1 510-871-6100 |
| 設立年月日 | 42217 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 100人 |
| url | www.gritstoneoncology.com |
| nasdaq_url | https://www.nasdaq.com/symbol/grts |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -53.00400 |
| 終値（lastsale） | 11.88 |
| 時価総額（marketcap） | 0 |
| 時価総額 | 時価総額（百万ドル） 423.78200 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 535.66500 |
| 当期純利益 | 当期純利益（百万ドル） -55.66800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Gritstone Oncology Inc revenues was not reported. Net loss increased 98% to $28.8M. Higher net loss reflects Research and development - Bala increase from $11.5M to $23.5M (expense) General and administrative - increase of 57% to $4.3M (expense) Stock-based Compensation in SGA increase from $111K to $578K (expense). |
GRTSのテクニカル分析
GRTSのニュース
Gritstone bio: Q4 2023 Data Readout Is Going To Be Major Inflection Point (NASDAQ:GRTS) 2023/04/23 08:25:21 Seeking Alpha
Results from phase 2/3 GRANITE study to treat patients with metastatic microsatellite stable colorectal cancer are expected in Q4 of 2023. Find out why GRTS stock is a Strong Buy.
Evercore ISI new coverage Gritstone Oncology Outperform 2023/03/31 11:30:35 Investing.com
https://www.investing.com/news/pro/gritstone-oncology-inc-receives-investment-bank-analyst-rating-update-3046228
FATE, GRTS and KZR are among after hour movers 2023/03/28 21:27:17 Seeking Alpha
Gainers: Arcturus Therapeutics (ARCT) +15%. lululemon athletica (LULU) +11%
Gritstone bio draws Buy rating at B. Riley on mRNA potential 2023/03/28 17:41:06 Seeking Alpha
Gritstone bio (GRTS) shares gained Tuesday after B. Riley launched its coverage with a Buy rating noting its prospects in messenger RNA technology. Read more here.
A Peek At Gritstone bio''s Pipeline (NASDAQ:GRTS) 2023/03/21 04:06:20 Seeking Alpha
Gritstone bio is focused on developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Find out why GRTS stock is a Hold.
Gritstone bio Inc. (GRTS) Q4 2022 Results - Earnings Call Transcript 2023/03/10 03:21:06 Seeking Alpha
Gritstone bio Inc. (NASDAQ:NASDAQ:GRTS) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ETCompany ParticipantsGeorge MacDougall - Director, Investor Relations and Corporate…
Gritstone Oncology GAAP EPS of -$1.32 beats by $0.10, revenue of $19.95M beats by $1.36M 2023/03/09 21:31:56 Seeking Alpha
Gritstone Oncology press release (GRTS): FY GAAP EPS of -$1.32 beats by $0.10.Revenue of $19.95M (-58.6% Y/Y) beats by $1.36M.Cash, cash equivalents, marketable securities…
Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates 2023/03/09 21:05:00 GlobeNewswire
-- Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals from “off-the-shelf” vaccine program (SLATE) consistent with those from GRANITE; randomized study of SLATE in patients with newly-diagnosed metastatic cancer to initiate in 2H 2023 --
Gritstone Oncology Q4 2022 Earnings Preview 2023/03/08 17:20:53 Seeking Alpha
Gritstone Oncology (GRTS) is scheduled to announce Q4 earnings results on Thursday, March 9th, after market close.The consensus EPS Estimate is -$0.34 and the consensus Revenue Estimate is…
Gritstone bio to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 9, 2023 2023/03/02 12:00:00 GlobeNewswire
Conference call to begin at 4:30pm ET on March 9 Conference call to begin at 4:30pm ET on March 9
Following Its 52-Week Low, Gritstone bio Inc. (NASDAQ: GRTS)’S Share Price Rose 47.71% And Its YTD Numbers Fell -74.57% 2022/12/30 13:30:00 Marketing Sentinel
During the last session, Gritstone bio Inc. (NASDAQ:GRTS)’s traded shares were 1.07 million, with the beta value of the company hitting 0.54. At the end of the trading day, the stock’s price was $3.27, reflecting an intraday gain of 8.64% or $0.26. The 52-week high for the GRTS share is $13.45, that puts it down … Following Its 52-Week Low, Gritstone bio Inc. (NASDAQ: GRTS)’S Share Price Rose 47.71% And Its YTD Numbers Fell -74.57% Read More »
Gritstone bio Inc. (NASDAQ: GRTS): Still A Hot Buy? 2022/12/19 15:00:00 Stocks Register
Gritstone bio Inc. (NASDAQ:GRTS) price closed lower on Friday, December 16, dropping -4.19% below its previous close. A look at the daily price movement shows that the last close reads $3.58, with intraday deals fluctuated between $3.335 and $3.90. The company’s 5Y monthly beta was ticking 0.56. Taking into account the 52-week price action we … Gritstone bio Inc. (NASDAQ: GRTS): Still A Hot Buy? Read More »
Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference 2022/12/15 21:31:00 GlobeNewswire
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference occurring January 9-12, 2023 in San Francisco. The presentation will take place on Thursday, January 12, 2023 from 9:45 - 10:25 AM Pacific Time in Elizabethan A conference room.
GRTS stock rallies after U.S. patent win for mRNA-based vaccine tech (NASDAQ:GRTS) 2022/12/13 15:08:40 Seeking Alpha
Gritstone bio (GRTS) surged Tuesday after announcing that the U.S. regulators issued two new patents covering its self-amplifying mRNA vaccine platform technology. Read the full story here.
How did Gritstone bio Inc. (GRTS) fare last session? 2022/11/28 15:16:00 US Post News
Gritstone bio Inc. (NASDAQ:GRTS) marked $3.16 per share on Friday, down from a previous closing price of $3.25. While Gritstone bio Inc. has underperformed by -2.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GRTS fell by -70.85%, with highs and lows ranging from $14.42 to […]